Flozins in heart failure – a new reimbursement indication

Jakub Olszewski; Katarzyn Kozon; Andrzej Patyra

doi:10.56782/pps.35

Published : 2022-06-14

Vol. 20 No. 1 (2022)

Flozins in heart failure – a new reimbursement indication

Jakub Olszewski

Katarzyn Kozon

Andrzej Patyra

DOI: https://doi.org/10.56782/pps.35

Abstract

Sodium-glucose cotransporter-2 inhibitors, called flozins, are a relatively new group of drugs that quickly have gained recognition among diabetologists, cardiologists, and nephrologists. The mechanism of their action is based on inhibition of the reabsorption of glucose inside the proximal tubule of nephron, which results in lowering a blood glucose level. In addition, flozins reduce blood pressure, cause weight loss, and reduce the risk of death from cardiovascular causes. Until recently, the potential of flozins was used only to treat patients with type 2 diabetes. The clinical trials published several years ago on three representatives of this group of drugs: dapagliflozin, empagliflozin, and canagliflozin, showed that their use in patients with type 2 diabetes and cardiovascular disease reduces the risk of hospitalization and death from cardiovascular causes. These trials prompted scientists to extend research on the effectiveness of flozins in lowering the risk of complications of heart failure and cardiovascular diseases. Subsequent studies showed that regardless of whether a patient with cardiovascular disease has diabetes, the effectiveness of empagliflozin and dapagliflozin is comparable in reducing hospitalizations and cardiovascular deaths. These discoveries resulted in flozins appearing in the European Society of Cardiology guidelines as one of the first-line drugs in heart failure with reduced ejection fraction. In Poland, empagliflozin, and dapagliflozin obtained a new reimbursement indication on May 1, 2022 – chronic heart failure with reduced ejection fraction in patients meeting specific criteria. It’s a significant step in treating heart failure, which is still a substantial cause of death and hospitalizations in Poland, especially among the aging population. The aim of this review is to show the path that flozins have gone from being an antidiabetic drug to being the first-line drug in the treatment of heart failure and to draw the attention of readers to the new reimbursement indication of flozins in Poland.

Keywords:

flozins, empagliflozin, dapagliflozin, diabetes, heart failure

Most read articles by the same author(s)

Katarzyna Kozon, Małgorzata Krzyżanowska, Jakub Olszewski, Andrzej Patyra, Spinal muscular atrophy – the effectiveness of treatment and new therapeutic possibilities for selected groups of patients in Poland , Prospects in Pharmaceutical Sciences: Vol. 21 No. 2 (2023)
Andrzej Patyra, Marcin Kołakowski, Marta Katarzyna Dudek, Anna Karolina Kiss, Isolation of trachelogenin 4-O-β-D-glucoside from the fruits of Carthamus tinctorius L. , Prospects in Pharmaceutical Sciences: Vol. 20 No. 2 (2022)
Adam Piasecki, Magdalena Sitnik, Jakub Olszewski, Maciej Bara, Katarzyna Herjan, Piotr Armański, The changing landscape of mineralocorticoid receptor antagonists – finerenone in cardiovascular and renal health , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Andrzej Patyra, Grzegorz Witkowski, Voltage-gated sodium channels mutations and their role in epilepsy , Prospects in Pharmaceutical Sciences: Vol. 20 No. 1 (2022)
Małgorzata Krzyżanowska, Katarzyna Kozon, Jakub Olszewski, Andrzej Patyra, Efficacy of satralizumab therapy in the treatment of NMOSD , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)
Andrzej Patyra, Twenty years of Prospects in Pharmaceutical Sciences: recent changes , Prospects in Pharmaceutical Sciences: Vol. 21 No. 3 (2023)

Details

References

Statistics

Authors

Download files

PDF (Język Polski)

Citation rules

Olszewski, J., Kozon, K., & Patyra, A. (2022). Flozins in heart failure – a new reimbursement indication. Prospects in Pharmaceutical Sciences, 20(1), 19–25. https://doi.org/10.56782/pps.35

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015, 373, 2117-2128, doi:10.1056/NEJMoa1504720. DOI: https://doi.org/10.1056/NEJMoa1504720

Sjöström, C.D.; Johansson, P.; Ptaszynska, A.; List, J.; Johnsson, E. Dapagliflozin lowers blood pressure in hypertensive and non-hypertensive patients with type 2 diabetes. Diab Vasc Dis Res 2015, 12, 352-358, doi:10.1177/1479164115585298. DOI: https://doi.org/10.1177/1479164115585298

Neal, B.; Perkovic, V.; Mahaffey, K.W.; de Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017, 377, 644-657, doi:10.1056/NEJMoa1611925. DOI: https://doi.org/10.1056/NEJMoa1611925

Johnston, R.; Uthman, O.; Cummins, E.; Clar, C.; Royle, P.; Colquitt, J.; Tan, B.K.; Clegg, A.; Shantikumar, S.; Court, R.; et al. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation. Health Technol Assess 2017, 21, 1-218, doi:10.3310/hta21020. DOI: https://doi.org/10.3310/hta21020

EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Forxiga Available online: https://www.ema.europa.eu/en/documents/assessment-report/forxiga-epar-public-assessment-report_en.pdf. (accessed on 25.05.2022).

EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Invokana. Available online: https://www.ema.europa.eu/en/documents/assessment-report/invokana-epar-public-assessment-report_en.pdf. (accessed on 25.05.2022).

EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Jardiance Available online: https://www.ema.europa.eu/en/documents/assessment-report/jardiance-epar-public-assessment-report_en.pdf (accessed on 25.05.2022).

EMA. Sprawozdanie Europejskiej Agencji Leków z oceny preparatu Steglarto Available online: https://www.ema.europa.eu/en/documents/assessment-report/steglatro-epar-public-assessment-report_en.pdf (accessed on 25.05.2022).

Markham, A.; Elkinson, S. Luseogliflozin: first global approval. Drugs 2014, 74, 945-950, doi:10.1007/s40265-014-0230-8. DOI: https://doi.org/10.1007/s40265-014-0230-8

Rosenwasser, R.F.; Rosenwasser, J.N.; Sutton, D.; Choksi, R.; Epstein, B. Tofogliflozin: a highly selective SGLT2 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 2014, 50, 739-745, doi:10.1358/dot.2014.50.11.2232267. DOI: https://doi.org/10.1358/dot.2014.50.11.2232267

Kashiwagi, A.; Shestakova, M.V.; Ito, Y.; Noguchi, M.; Wilpshaar, W.; Yoshida, S.; Wilding, J.P.H. Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Ther 2019, 10, 2201-2217, doi:10.1007/s13300-019-00699-8. DOI: https://doi.org/10.1007/s13300-019-00699-8

Markham, A. Remogliflozin Etabonate: First Global Approval. Drugs 2019, 79, 1157-1161, doi:10.1007/s40265-019-01150-9. DOI: https://doi.org/10.1007/s40265-019-01150-9

Bednarz, K.; Siuda, J. Alzheimer's disease and type 2 diabetes mellitus: similarities in pathomechanisms lead to therapeutic opportunities. Neurol Neurochir Pol 2021, 55, 418-428, doi:10.5603/PJNNS.a2021.0056. DOI: https://doi.org/10.5603/PJNNS.a2021.0056

Kautzky-Willer, A.; Harreiter, J.; Pacini, G. Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. Endocr Rev 2016, 37, 278-316, doi:10.1210/er.2015-1137. DOI: https://doi.org/10.1210/er.2015-1137

Araszkiewicz, A.; Bandurska-Stankiewicz, E.; Borys, S.; Budzyński, A.; Cyganek, K.; Cypryk, K.; Czech, A.; Czupryniak, L.; Drzewoski, J.; Dzida, G.; et al. 2021 Guidelines on the management of patients with diabetes. A position of Diabetes Poland. Clinical Diabetology 2021, 10, 1-113, doi:10.5603/dk.2021.0001. DOI: https://doi.org/10.5603/DK.2021.0001

Cosentino, F.; Grant, P.J.; Aboyans, V.; Bailey, C.J.; Ceriello, A.; Delgado, V.; Federici, M.; Filippatos, G.; Grobbee, D.E.; Han-sen, T.B.; et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020, 41, 255-323, doi:10.1093/eurheartj/ehz486. DOI: https://doi.org/10.1093/eurheartj/ehz486

Kałużna-Oleksy, M. Niewydolność serca w Polsce - Realia, koszty, sugestie poprawy sytuacji; Porozumienie Organizacji Kar-diologicznych – Razem dla Serca: 2020.

Disease, G.B.D.; Injury, I.; Prevalence, C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211-1259, doi:10.1016/S0140-6736(17)32154-2. DOI: https://doi.org/10.1016/S0140-6736(17)32154-2

Nessler, J.; Siniarski, A.; Leszek, P.; Gumprecht, J.; Drożdż, J.; Kaźmierczak, J.; Witkowski, A.; Gackowski, A.; Jankowska, E.A.; Kukulski, T.; et al. Zastosowanie dapagliflozyny w leczeniu niewydolności serca ze zmniejszoną frakcją wyrzutową lewej komory. Kar-diologia Polska (Polish Heart Journal) 2021, 79, 143-151. DOI: https://doi.org/10.33963/KP.15859

Nessler, J.; Kozierkiewicz, A.; Gackowski, A.; Ponikowski, P.; Hryniewiecki, T.; Gruchała, M.; Gąsior, M.; Grodzicki, T.; Kaź-mierczak, J.; Legutko, J.; et al. Comprehensive Heart Failure Care pilot study: starting point and expected developments. Kardiol Pol 2019, 77, 994-999, doi:10.33963/kp.15035. DOI: https://doi.org/10.33963/KP.15035

Wiviott, S.D.; Raz, I.; Bonaca, M.P.; Mosenzon, O.; Kato, E.T.; Cahn, A.; Silverman, M.G.; Zelniker, T.A.; Kuder, J.F.; Murphy, S.A.; et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019, 380, 347-357, doi:10.1056/NEJMoa1812389. DOI: https://doi.org/10.1056/NEJMoa1812389

Kluger, A.Y.; Tecson, K.M.; Barbin, C.M.; Lee, A.Y.; Lerma, E.V.; Rosol, Z.P.; Rangaswami, J.; Lepor, N.E.; Cobble, M.E.; McCullough, P.A. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review. Rev Cardiovasc Med 2018, 19, 41-49, doi:10.31083/j.rcm.2018.02.907. DOI: https://doi.org/10.31083/j.rcm.2018.02.907

McMurray, J.J.V.; Solomon, S.D.; Inzucchi, S.E.; Køber, L.; Kosiborod, M.N.; Martinez, F.A.; Ponikowski, P.; Sabatine, M.S.; Anand, I.S.; Bělohlávek, J.; et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 2019, 381, 1995-2008, doi:10.1056/NEJMoa1911303. DOI: https://doi.org/10.1056/NEJMoa1911303

Packer, M.; Anker, S.D.; Butler, J.; Filippatos, G.; Pocock, S.J.; Carson, P.; Januzzi, J.; Verma, S.; Tsutsui, H.; Brueckmann, M.; et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 2020, 383, 1413-1424, doi:10.1056/NEJMoa2022190. DOI: https://doi.org/10.1056/NEJMoa2022190

McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021, 42, 3599-3726, doi:10.1093/eurheartj/ehab368. DOI: https://doi.org/10.1093/eurheartj/ehab368

FDA. Komunikat prasowy FDA dotyczący zatweirdzenia Dapagliflozyny w leczeniu HFrEF. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-type-heart-failure (accessed on 25.05.2022).

Anker, S.D.; Butler, J.; Filippatos, G.; Ferreira, J.P.; Bocchi, E.; Böhm, M.; Brunner-La Rocca, H.P.; Choi, D.J.; Chopra, V.; Chuquiure-Valenzuela, E.; et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med 2021, 385, 1451-1461, doi:10.1056/NEJMoa2107038. DOI: https://doi.org/10.1056/NEJMoa2107038

FDA. Komunikat prasowy FDA dotyczący zatwierdzenia empagliflozyny u pacjentów w HFpEF. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-treatment-wider-range-patients-heart-failure (accessed on 25.05.2022).

Obwieszczenie Ministra Zdrowia z dnia 20 kwietnia 2022 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 maja 2022 r. Available online: https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-20-kwietnia-2022-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych-na-1-maja-2022-r (accessed on 25.05.2022).

Jakub Olszewski

olszewskij3@gmail.com

Affiliation:

Student's Scientific Group, Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland Poland

Katarzyn Kozon

Affiliation:

Student's Scientific Group, Department of Nephrology, Dialysis and Internal Medicine, Medical University of Warsaw, Warsaw, Poland Poland

Andrzej Patyra

andrzej.patyra@wum.edu.pl
https://orcid.org/0000-0003-4981-6660

Affiliation:

Department of Pharmacognosy and Molecular Basis of Phytotherapy, Medical University of Warsaw, Warsaw, Poland; Doctoral School, Medical University of Warsaw, Warsaw, Poland; Institut des Biomolécules Max Mousseron, Université de Montpellier, CNRS, ENSCM, Montpellier, France Poland